1. Home
  2. PMCB vs FRSX Comparison

PMCB vs FRSX Comparison

Compare PMCB & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.44

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Logo Foresight Autonomous Holdings Ltd.

FRSX

Foresight Autonomous Holdings Ltd.

N/A

Current Price

$1.15

Market Cap

5.1M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
PMCB
FRSX
Founded
1996
N/A
Country
United States
Israel
Employees
N/A
74
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.3M
5.1M
IPO Year
2001
2016

Fundamental Metrics

Financial Performance
Metric
PMCB
FRSX
Price
$0.44
$1.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 302.6K
81.7K
Earning Date
03-17-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.78
52 Week High
$1.51
$3.00

Technical Indicators

Market Signals
Indicator
PMCB
FRSX
Relative Strength Index (RSI) 44.03 46.94
Support Level $0.33 $1.05
Resistance Level $0.77 $1.47
Average True Range (ATR) 0.05 0.08
MACD 0.01 0.02
Stochastic Oscillator 63.10 39.32

Price Performance

Historical Comparison
PMCB
FRSX

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.

Share on Social Networks: